PLEURAL FLUID FOR MALIGNANT CELLS

Malignant pleural effusion (MPE) stands as a prevalent and serious health concern, significantly impacting the well-being, morbidity, and mortality of affected individuals. The escalating incidence of MPE, coupled with the associated healthcare costs, underscores the urgent need for advanced management solutions. Despite progress, the current approach remains largely palliative, with median survival rates ranging from 3 to 12 months. Over the past decade, HYPRO Diagnostics has played a pivotal role in advancing the understanding of MPE’s pathophysiology, refining diagnostic methods, improving imaging techniques, and transforming patient management. Today, patients previously confined to beds undergo genotyping, phenotyping, and receive ambulatory care. This article from HYPRO Diagnostics aims to provide a thorough overview of recent strides in MPE research, spanning from laboratory insights to practical applications at the bedside. It not only illuminates the evolving landscape of MPE but also highlights lingering questions in clinical practice, guiding future directions for both basic and clinical research within the field.